Patent intelligence · Companies
Company patent strength
Non-educational filers ranked by their patent portfolio. Grant rate and lapsed share expose where high filing volume is not matched by granted patents. Domestic filers lead — toggle to foreign applicants to see who is entering the Indian market.
Free to browse the ranking. Sign into open a filer's full profile — inventors, filing trend and quality index. See how we rank.
Why this page exists — and how to read it
Filing volume and IP quality are different things. This leaderboard ranks non-educational filers by portfolio, but the grant-rate and lapsed sorts are where the judgement lives: they separate companies whose filings survive examination from those accumulating paper.
- Investors
- High grant rate on steady filing usually means a real R&D engine; big volume with a high lapsed share is a red flag worth asking about.
- Founders & operators
- These are the incumbents and potential acquirers in your space — open a filer to see the walls you'd build against.
- Corporate & R&D
- Benchmark competitors' portfolios and grant rates; toggle to foreign to watch who is entering the Indian market.
💬 The grant-rate sort applies a 20-filing floor so tiny portfolios can't top the list.
3,207 foreign filers with 5+ patents · page 33
| # | Filer | Patents↓ | Granted↓ | Lapsed↓ | Pending↓ | Active |
|---|---|---|---|---|---|---|
| 1601 | KNAUF GIPS KG | 9 | 111.1% | 0 | 8 | 2022–2025 |
| 1602 | KYB MOTORCYCLE SUSPENSION | 9 | 111.1% | 0 | 8 | 2022–2025 |
| 1603 | KYOCERA | 9 | 00% | 0 | 9 | 2024–2026 |
| 1604 | LANDA LABS 2012 | 9 | 00% | 0 | 9 | 2022–2025 |
| 1605 | LANSUS TECHNOLOGIES | 9 | 111.1% | 0 | 8 | 2023–2024 |
| 1606 | LEDGER | 9 | 00% | 0 | 9 | 2025–2026 |
| 1607 | LEYBOLD | 9 | 00% | 3 | 6 | 2022–2026 |
| 1608 | LYONDELL CHEMICAL TECHNOLOGY L P | 9 | 444.4% | 2 | 3 | 2022–2024 |
| 1609 | LYONDELLBASELL ACETYLS | 9 | 222.2% | 0 | 7 | 2022–2026 |
| 1610 | M TECHNIQUE | 9 | 111.1% | 3 | 5 | 2022–2024 |
| 1611 | MAHLE ANAND THERMAL SYSTEMS | 9 | 333.3% | 0 | 6 | 2022–2025 |
| 1612 | MARS | 9 | 00% | 0 | 9 | 2022–2025 |
| 1613 | MATSUMOTO YUSHI SEIYAKU | 9 | 222.2% | 0 | 7 | 2022–2026 |
| 1614 | METAMORPHOSIS | 9 | 111.1% | 0 | 8 | 2022–2026 |
| 1615 | MITSUBOSHI BELTING | 9 | 00% | 0 | 9 | 2022–2026 |
| 1616 | MORPHOSYS | 9 | 00% | 0 | 9 | 2022–2024 |
| 1617 | MYELOID THERAPEUTICS | 9 | 00% | 0 | 9 | 2022–2025 |
| 1618 | NAMYANG NEXMO | 9 | 00% | 0 | 9 | 2024–2025 |
| 1619 | NANEXA | 9 | 00% | 2 | 7 | 2022–2025 |
| 1620 | NEO PERFORMANCE MATERIALS SINGAPORE | 9 | 00% | 0 | 9 | 2022–2025 |
| 1621 | NET INSIGHT | 9 | 00% | 1 | 8 | 2022–2025 |
| 1622 | NETZSCH PUMPEN SYSTEME | 9 | 00% | 0 | 9 | 2022–2025 |
| 1623 | NEURODERM | 9 | 111.1% | 2 | 6 | 2022–2025 |
| 1624 | NIDEC GLOBAL APPLIANCE BRASIL LTDA | 9 | 00% | 2 | 7 | 2022–2025 |
| 1625 | NIPPON ELECTRIC GLASS | 9 | 111.1% | 0 | 8 | 2022–2026 |
| 1626 | NIPPON THERMOSTAT | 9 | 111.1% | 2 | 6 | 2022–2025 |
| 1627 | NOHMS TECHNOLOGIES | 9 | 00% | 9 | 0 | 2022–2023 |
| 1628 | NOKIA SHANGHAI BELL | 9 | 333.3% | 1 | 5 | 2020–2025 |
| 1629 | NORMA GERMANY | 9 | 222.2% | 1 | 6 | 2022–2024 |
| 1630 | NTT COMMUNICATIONS | 9 | 00% | 0 | 9 | 2022–2025 |
| 1631 | NUANCE COMMUNICATIONS | 9 | 00% | 0 | 9 | 2022–2023 |
| 1632 | OERLIKON CHINA TECHNOLOGY | 9 | 00% | 0 | 9 | 2024–2025 |
| 1633 | OMEROS | 9 | 00% | 0 | 9 | 2022–2026 |
| 1634 | OTSUKA CHEMICAL | 9 | 111.1% | 1 | 7 | 2022–2025 |
| 1635 | PUNCH POWERTRAIN PSA E TRANSMISSIONS | 9 | 111.1% | 1 | 7 | 2022–2024 |
| 1636 | PURPLE INNOVATION | 9 | 00% | 0 | 9 | 2023–2026 |
| 1637 | QSC | 9 | 111.1% | 1 | 7 | 2022–2025 |
| 1638 | R STAHL SCHALTGER TE | 9 | 333.3% | 0 | 6 | 2021–2025 |
| 1639 | RICARDO UK | 9 | 00% | 0 | 9 | 2022–2024 |
| 1640 | SAINT GOBAIN WEBER FRANCE | 9 | 00% | 0 | 9 | 2022–2025 |
| 1641 | SANDEN | 9 | 00% | 0 | 9 | 2023–2025 |
| 1642 | SANYO CHEMICAL INDUSTRIES | 9 | 333.3% | 1 | 5 | 2022–2025 |
| 1643 | SCHOTT PHARMA KGAA | 9 | 111.1% | 0 | 8 | 2020–2025 |
| 1644 | SECO TOOLS | 9 | 444.4% | 0 | 5 | 2022–2025 |
| 1645 | SEKAB E TECHNOLOGY | 9 | 00% | 3 | 6 | 2022–2023 |
| 1646 | SEQIRUS | 9 | 00% | 0 | 9 | 2025–2026 |
| 1647 | SHANGHAI JUNSHI BIOSCIENCES | 9 | 00% | 4 | 5 | 2022–2025 |
| 1648 | SHIKOKU CHEMICALS | 9 | 111.1% | 0 | 8 | 2022–2026 |
| 1649 | SHOPIFY | 9 | 00% | 1 | 8 | 2022–2022 |
| 1650 | SIGILON THERAPEUTICS | 9 | 00% | 1 | 8 | 2022–2024 |
Educational institutes are excluded — see the institute leaderboard. Attribution is by patent assignee record; a jointly-owned patent is credited to each co-owner, so a co-filed patent counts for every company on it. "Lapsed" = abandoned, withdrawn, deemed-withdrawn or refused; "Pending" = awaiting examination or in prosecution. Want to filter by technology or value category? Browse the filer explorer →
Rankings use patent-registry status (grant rate, examination, claim depth) as a quality proxy — directional, not advice; see methodology. Read the ranking methodology →